THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 27, 2006--Amgen (NASDAQ:AMGN), the world’s largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp(R) (darbepoetin alfa) for the treatment of chemotherapy-induced anemia (low red blood cell count) in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent approved by the FDA for every-three-week administration.
